More on VSTM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.17 |
|
|||
| Open | $4.24 | ||||
| 52 Wk High | $2.43 | ||||
| 52 Wk Low | $1.05 | ||||
| Day High | $4.43 | ||||
| Day Low | $4.11 | ||||
| P/E | N/A | ||||
| EPS | $-1.79 | ||||
| Volume | 4,766,027 | ||||
- Mizuho Reiterates Outperform Rating on Verastem (VSTM), maintain "June top pick"
- Form 8-K Verastem, Inc. For: Jun 16
- Verastem reports 86% six-month survival rate in pancreatic cancer trial
- Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
- VERASTEM doses first patient in Phase 2 pancreatic cancer trial
- Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
- Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
- Buy this biotech stock now, Mizuho urges
- FDA grants fast track status to Verastem's lung cancer drug VS-7375
- Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally
Entities mentioned with VSTM
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Definitive Agreement | View Related Stories »
- Pre Market Movers | View Related Stories »
- Show More...
